Study S001430

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Efsubaglutide Alfa Injection in Subjects With Overweight or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07114419
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 200
Start: 2025-08-25
Primary completion: 2026-06-01
Lead sponsor: Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Conditions: Obesity and Overweight
Interventions: DRUG:Efsubaglutide Alfa 20 mg QW; DRUG:Efsubaglutide Alfa 40 mg QW; DRUG:Efsubaglutide Alfa 40 mg Q2W; DRUG:Efsubaglutide Alfa 80 mg QW; DRUG:Efsubaglutide Alfa 80 mg Q4W; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:YN012-II-W204-AU

Registered primary outcomes

Percentage change (%) of body weight from baseline after subcutaneous administration of YN-011 for 22 weeks [22 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.